Sunday, November 24, 2024
11/24/2024
Abstract Increases in Opioid Use Disorder (OUD) in the last decade has created a public health crisis. Methadone maintenance treatment (MMT) is the most common treatment for OUD. While MMT is effective in helping patients improve their quality of life, physical and mental health comorbidities are common and increase risk for premature death. While unhealthy lifestyle behaviors such as physical inactivity and cigarette smoking have been targeted, the role of nutritional intake in this population has been relatively unexplored. Clinically significant increases in weight (at least 10%) have been consistently observed, as well as oft-reported cravings for sweet foods upon MMT initiation. Missing from the existing literature is a clear understanding of why this phenomenon occurs, limiting the ability to effectively target this problem with appropriate intervention. Purported explanations for weight gain have included increased food intake to compensate for undernourishment during the time of active illicit opioid use and the pharmacological effects of methadone on pancreatic cell dysfunction and sweet taste preference. However, these possibilities may only partially explain weight gain as most patients starting treatment are already overweight or obese and increases in weight continue even when methadone doses are stable. We are proposing an additional hypothesis: patients starting MMT will consume foods that are highly palatable (HPF; i.e., high in fat, sugar, or both) in an effort to manage negative affect and opioid cravings that are common during early recovery. Anecdotal reports of patients in substance use treatment provide support for this hypothesis – HPF provide emotional relief and decrease drug cravings. An emerging body of basic science literature demonstrates shared neural mechanisms of both HPF and drugs of abuse. As with drugs, HPF potentiates endogenous opioid and dopamine release in the nucleus accumbens, which, through repeated overconsumption, can also lead to disrupted reward pathways. Indeed, in non-substance using populations, overconsumption of HPF can lead to poorer psychological functioning such as depression and anxiety (known relapse risks in those with OUD). Therefore, while HPF may have a short-term beneficial effect on improving negative affect and decreasing opioid cravings among patients in MMT, it may also confer a longer-term risk for relapse in this population. Understanding the within-person associations between negative affect, opioid cravings, and consumption of HPF at the daily level and over the course of early MMT initiation is critical for informing the development of adjunctive, nutrition-focused interventions in this at-risk population. We propose to conduct a 26-week prospective study of 80 patients who recently initiated MMT utilizing ecological momentary assessment (EMA; through three, 21-day bouts). In doing so, we can answer the question of whether HPF consumption during early MMT is beneficial or detrimental to risk for returning to illicit opioid use. With this information, more effective interventions could be developed to extend recovery and decrease the public health impact of OUD.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
